Alisertib (MLN8237)

Catalog No.S1133

Alisertib (MLN8237) Chemical Structure

Molecular Weight(MW): 518.92

Alisertib (MLN8237) is a selective Aurora A inhibitor with IC50 of 1.2 nM in a cell-free assay. It has >200-fold higher selectivity for Aurora A than Aurora B. Phase 3.

Size Price Stock Quantity  
In DMSO USD 168 In stock
USD 120 In stock
USD 210 In stock
USD 670 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Cited by 48 Publications

12 Customer Reviews

  • Inhibition of Aurka kinase activity by MLN8237 impairs expression of pluripotency genes in CCE cells as measured by qRT-PCR. All values shown are mean ?SEM for n=3. The level of phosphorylated H3(S10) (p-H3(S10)), an Aurka phosphorylation target site, is decreased in MLN8237-treated samples.

    Cell Stem Cell 2012 11, 179-94. Alisertib (MLN8237) purchased from Selleck.

    Recruitment of clathrin to the mitotic spindle is controlled by phosphorylation of TACC3 by Aurora-A kinase. Representative micrographs of HEK293 cells incubated with 0.3 μM MLN8237 for 40 min. Cells were fixed and stained as indicated.

    EMBO J 2012 30, 906-19. Alisertib (MLN8237) purchased from Selleck.

  • Aurora A inhibition rescues the PPP6C depletion phenotype. (A) HeLa cells transfected for 48 h with control and PPP6C si08 duplexes were treated with 10 or 20 nM MLN8237 or a solvent control for 15 min before lysis in phosphatase inhibitor containing buffer or fixation. Total lysates were analyzed by Western blotting. The red and black lines indicate the hosphorylated and nonphosphorylated forms of Aurora A. Fixed cells were stained using DAPI to detect DNA and antibodies to α-tubulin and Aurora A pT288. The intensity of pT288 staining was integrated using ImageJ over the spindle region defined by TPX2 staining and is plotted in the bar graph ( n = 4). Arrowheads indicate micronuclei. Bar, 5 µm. (B) HeLa cells transfected for 48 h with control and PPP6C si08 duplexes were treated with 10 nM MLN8237 or a solvent control for 24 h before fixation and staining with DAPI to detect DNA.

    J Cell Biol 2010 191, 1315-32. Alisertib (MLN8237) purchased from Selleck.

    NUSAP mitotic phosphorylation at Ser 240 correlates with Aurora A activity. Protein samples of FLAG-NUSAP immunoprecipitated from I, M and MtMLN or with MtZM were analysed using LC-MS/MS, focusing on the predicted phosphorylated residue Ser 240. The histograms (A, B) show the calculated ratios based on peptides carrying the phosphorylated Ser 240 compared with all matched peptides containing this residue.

     

     

    EMBO reports 2010 11, 977-984. Alisertib (MLN8237) purchased from Selleck.

  • D) Pharmacological inhibition of AURKA using alisertib led to downregulation of p-EIF4E (S209) and c-MYC proteins in FLO-1 and SK-GT-4 resistant cells, with or without RAD001 treatment.

    Clin Cancer Res, 2017.. Alisertib (MLN8237) purchased from Selleck.

    Tissue levels of 53BP1, a-tubulin, IkB-a and IL-6 in an Hs294T xenograft treated with MLN8237 or vehicle control were visualized by immunofluorescence co-staining with DAPI. Representative micrographs are shown from triplicate experiments.

    EMBO Mol Med 2013 5(1), 149-66. Alisertib (MLN8237) purchased from Selleck.

  • Alisertib inhibits AURKA and AURKB in a concentration-dependent manner. (a) Alisertib induces G 2 /M delay or genome reduplication. HeLa cells were exposed to buffer or the indicated concentrations of Alisertib. After 24 h, the cells were harvested and analyzed with flow cytometry. The positions of 2N, 4N and 8N DNA contents are indicated. (b) Alisertib delays mitotic exit or induces slippage. HeLa cells stably expressing histone H2B-GFP were exposed to buffer or the indicated concentrations of Alisertib. Individual cells were then tracked for 24 h with time-lapse microscopy. Each horizontal bar represents one cell (n ¼ 50). Key: light gray ¼ interphase; black ¼ mitosis (from DNA condensation to anaphase or mitotic slippage); dark gray ¼ interphase after mitotic slippage; truncated bars ¼ cell death. (c) Different concentrations of Alisertib are involved in delaying mitotic exit and inducing slippage. Live-cell imaging of cells treated with Alisertib was described in panel (b). The duration of mitosis (mean±90% confidence interval) and the percentage of cells that underwent mitotic slippage during the imaging period was quantified. (d) Alisertib promotes apoptosis in a concentration-dependent manner. HeLa cells were incubated with the indicated concentrations of Alisertib for 48 h. The cells were then harvested and analyzed with flow cytometry. (e) Concentration-dependent cytotoxicity of Alisertib. HeLa cells were cultured in the presence of the indicated concentrations of Alisertib for 48 h. The number of live and dead cells was analyzed with trypan blue exclusion assay. (f) Concentration-dependent suppression of long-term survival by Alisertib. HeLa cells were seeded on 60-mm culture plates and grown in the presence of 250 n M or 1 m M of Alisertib. After 24 h, the cells were washed gently and propagated in normal medium for another 10–12 days. Colonies were fixed and stained with crystal violet solution (examples of the plates are shown). Average±s.d. from three independent experiments. (g) Both AURKA and AURKB are inhibited by Alisertib.Mitotic HeLa cells were obtained by exposure to nocodazole for 16 h followed by mechanical shake off. The cells were incubated with the indicated concentrations of Alisertib for 2 h. Lysates were then prepared and activated phospho-AURKAThr288 and AURKBThr232were detected with immunoblotting. The asterisk indicates the position of an AURKB-like protein (the same throughout this study). Uniform loading was confirmed by immunoblotting for actin. In this assay, nocodazole and MG132 (a proteasome inhibitor) were added to prevent the cells from exiting mitosis. Accordingly, the total AURKA and AURKB levels remained constant throughout the experiment. (h) Alisertib prevents activation of AURKA and AURKB. HeLa cells were incubated with the indicated concentrations of Alisertib for 8 h. Nocodazole was then added for another 6 h to trap cells that entered mitosis. Lysates were prepared and analyzed with immunoblotting. Actin analysis was included to assess loading and transfer.

    Oncogene 2014 33, 3550-60. Alisertib (MLN8237) purchased from Selleck.

    Inhibition of Aurora A (12.5 nM) by MLN8054 or MLN8237 was assessed in duplicate radiometric assays containing 100 μM [γ-32P] ATP and quantified by p81 phosphocellulose assay and scintillation counting. Kinase activity is reported as a percentage of control calculated from duplicate incubations containing 2.5% (v/v) DMSO. IC50 values represent the mean ±SEM calculated from two independent experiments.

     

     

    ACS Chem Biol 2010 5, 563-576. Alisertib (MLN8237) purchased from Selleck.

  • The effects of T217D and T217N Aurora A mutations were directly compared to WT Aurora A-expressing cells. Each well was treated with either DMSO or 500 nM MLN8054 (E), or 30 nM MLN8237 (F) on day one of the experiment and cells were cultured for 8 days, at which point they were fixed. For all colony assays, an area encompassing >90 % of the colonies per dish is shown. Similar results were seen in two independent duplicate experiments.

    ACS Chem Biol 2010 5, 563-576. Alisertib (MLN8237) purchased from Selleck.

    C, Fry depletion decreases the level of Thr-210 phosphorylation of Plk1 on spindle poles. HeLa cells transfected with siRNAs were cultured in growth medium for 12 h and in thymidine-containing medium for 36 h. They were then released from thymidine arrest for 12 h before being fixed and stained with anti-Plk1 pT210 ( green) and anti-pericentrin (red) antibodies. DNA was stained with TO-PRO-3 ( blue ). For Aurora A inhibition, after release from thymidine block for 10 h, HeLa cells transfected with control siRNA were incubated for2h in medium containing MLN8237 (100 nM) and MG132 (10 μM). Magnified images of the white boxes are also shown. Scale bar ,5 μm.

    J Biol Chem 2012 287, 27670-81. Alisertib (MLN8237) purchased from Selleck.

  • B, drug-treated cells were also stained with DAPI to visualize nuclear DNA and analyzed with a microscope equipped with a fluorescence digital CCD camera. Representative results are shown. Bar, 40 μm.

    J Biol Chem, 2017, 292(5):1910-1924. Alisertib (MLN8237) purchased from Selleck.

    Eg5 inhibition counteracts the induction of spindle pole fragmentation by Aurora-A inactivation. The protocol to inhibit Aurora-A by MLN8237 in cells progressing towards mitosis is depicted (time intervals not represented to scale). Control cultures were treated with solvent (DMSO) in the same time window. When indicated, MON was added 1 hour before harvesting. Note the absence of active phosphorylated (pThr288) Aurora-A (in red in IF panels) in cells treated with MLN8237. Upper histograms represent the percentage of all spindle and MT abnormalities in control and MLN8237-treated cultures (200 counted PM/M per condition in 2 experiments); the grey fraction of the histograms represents mitoses with spindle extrapoles, while other defects (monopolar or disorganised spindles, few and short MTs) are in white. Lower histograms and IF panels show that concomitant Eg5 inhibition by MON prevents MLN8237-induced spindle pole fragmentation (note the failure of centrosome migration reflecting Eg5 inactivation in lower IF panels). 200 PM/M per condition were counted in 2 experiments. Error bars represent s.d. **: p < 0.001, χ2 test. Red asterisks indicate significant differences with respect to DMSO controls, and black asterisks significant differences between Aurora-Ai mitoses with active or inactive Eg5. Scale bar: 10 μm

    Mol Cancer 2011 10, 131. Alisertib (MLN8237) purchased from Selleck.

Purity & Quality Control

Choose Selective Aurora Kinase Inhibitors

Biological Activity

Description Alisertib (MLN8237) is a selective Aurora A inhibitor with IC50 of 1.2 nM in a cell-free assay. It has >200-fold higher selectivity for Aurora A than Aurora B. Phase 3.
Features First orally available inhibitor of Aurora A.
Targets
Aurora A [1]
(Cell-free assay)
1.2 nM
In vitro

MLN8237 shows >200-fold higher selectivity for Aurora A than the structurally related Aurora B with an IC50 of 396.5 nM, and does not have any significant activity against 205 other kinases. [1] MLN8237 (0.5 μM) treatment inhibits the phosphorylation of Aurora A in MM1.S and OPM1 cells, without affecting the Aurora B mediated histone H3 phosphorylation. MLN8237 significantly inhibits cell proliferation in multiple myeloma (MM) cell lines with IC50 values of 0.003-1.71 μM. MLN8237 displays more potent anti-proliferation activity against primary MM cells and MM cell lines in the presence of BM stroma cells, as well as IL-6 and IGF-1 than against MM cells alone. MLN8237 (0.5 μM) induces 2- to 6-fold increase in G2/M phase in primary MM cells and cell lines, as well as significant apoptosis and senescence, involving the up-regulation of p53, p21 and p27, as well as PARP, caspase 3, and caspase 9 cleavage. In addition, MLN8237 shows strong synergistic anti-MM effect with dexamethasone, as well as additive effect with doxorubicin and bortezomib. [2] MLN8237 (0.5 μM) treatment causes the inhibition of colony formation of FLO-1, OE19, and OE33 esophageal adenocarinoma cell lines, and induces a significant increase in the percentage of polyploid cells, and subsequently an increase in the percentage of cells in the sub-G1 phase, which can be further enhanced in combination with cisplatin (2.5 μM), involving the higher induction of TAp73β, PUMA, NOXA, cleaved caspase-3, and cleaved PARP as compared with a single-agent treatment. [3]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
HCT116 NH\LXIhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWjHeJI3OC53IN88US=> MYS3NkBp NU\VVHNHTE2VTx?= MmLMTWM2OD1yLkC0JO69VQ>? MX[yOlE{PjZ6NB?=
LS174T MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3HYdlAvPSEQvF2= NEPXR3k4OiCq M1qycWROW09? M2DxbGlEPTB;MD6wOUDPxE1? MWKyOlE{PjZ6NB?=
T84 MmmwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{LqcVAvPSEQvF2= M1XaW|czKGh? NIfMUGNFVVOR M4\Yb2lEPTB;MD6wPUDPxE1? Ml7jNlYyOzZ4OES=
LS180 M2LJVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NES5cGMxNjVizszN M{jNXlczKGh? NFWydnJFVVOR M2e5SGlEPTB;MTFOwG0> NX:3NFd6OjZzM{[2PFQ>
SW948 M1jI[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkX6NE42KM7:TR?= M3jMTlczKGh? M{jXN2ROW09? Moj5TWM2OD1zIN88US=> NWXaNJZ{OjZzM{[2PFQ>
HCT15 NGPEblBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYTOS4xZOC53IN88US=> NGnQZ2s4OiCq MoHmSG1UVw>? Moi4TWM2ODxyLkSg{txO M1XTV|I3OTN4Nki0
DLD-1 Mme1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NG\3SYsxNjVizszN NFGxS|A4OiCq MlPBSG1UVw>? MV;JR|UxRDBwODFOwG0> M4e2XFI3OTN4Nki0
MIP-101 M2rLeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEDrdmYxNjVizszN NWLWe3hCPzJiaB?= MlmwSG1UVw>? MVzJR|UxRTFizszN NX75[XVvOjZzM{[2PFQ>
SNU1544 MmHYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYr3bIFjOC53IN88US=> MlLuO|IhcA>? MX7EUXNQ MV\JR|UxRTFizszN MUGyOlE{PjZ6NB?=
OCI-Ly10 MXnDfZRwfG:6aXOgRZN{[Xl? MmX0O|IhcA>? M33p[WROW09? MUHJR|UxRTBwMEW4JO69VQ>? MYGyOVg4QDN|MR?=
SU-DHL2 NYfqclNDS3m2b4TvfIlkKEG|c3H5 M3;nb|czKGh? MWLEUXNQ NIfuRnhKSzVyPUCuNFEh|ryP MWOyOVg4QDN|MR?=
OCI-LY7 NFfZTIdEgXSxdH;4bYMhSXO|YYm= NF3vfmo4OiCq MnfSSG1UVw>? NVznWWtSUUN3ME2wMlA5OSEQvF2= NVPYcGRPOjV6N{izN|E>
SU-DHL6 NYjrUoVYS3m2b4TvfIlkKEG|c3H5 NHHwZpM4OiCq NIHKUGhFVVOR Mo\JTWM2OD1yLkS4NkDPxE1? MYeyOVg4QDN|MR?=
Jeko-1 NFy5c4FEgXSxdH;4bYMhSXO|YYm= M16xdlczKGh? M{\DeWROW09? MljSTWM2OD1yLkCyPUDPxE1? NFXCNoozPTh5OEOzNS=>
JVM-2 MVnDfZRwfG:6aXOgRZN{[Xl? MorkO|IhcA>? MmHXSG1UVw>? NVnzeG5oUUN3ME2wMlAyKM7:TR?= NVfYO4dGOjV6N{izN|E>
Rec-1 M4HSUWN6fG:2b4jpZ{BCe3OjeR?= M3LOPVczKGh? NFziS41FVVOR MYPJR|UxRTBwMEi3JO69VQ>? MYCyOVg4QDN|MR?=
Z-138 NV;HW2NuS3m2b4TvfIlkKEG|c3H5 MYG3NkBp NI\JPVBFVVOR M3TacmlEPTB;MD6wNVMh|ryP MV2yOVg4QDN|MR?=
H9 MmfDR5l1d3SxeHnjJGF{e2G7 MWm3NkBp MVzEUXNQ NILVclFKSzVyPUCuOkDPxE1? NHe0SmEzPTh5OEOzNS=>
HH MkXBR5l1d3SxeHnjJGF{e2G7 MXq3NkBp M{XkZ2ROW09? MljMTWM2OD1yLkeg{txO NICxfXYzPTh5OEOzNS=>
DND41 M2rWOGN6fG:2b4jpZ{BCe3OjeR?= NGLFN2w4OiCq MVXEUXNQ NVLqXXpDUUN3ME2wMlEh|ryP NVzMN2JwOjV6N{izN|E>
CCL119 MWjDfZRwfG:6aXOgRZN{[Xl? NUTCVIU4PzJiaB?= MXXEUXNQ NHfSb5VKSzVyPUCuNFYzKM7:TR?= NWKzOm9lOjV6N{izN|E>
J.Cam 1.6 MULDfZRwfG:6aXOgRZN{[Xl? M4HXV|czKGh? NYTvdoNITE2VTx?= NI\zSZRKSzVyPUCuNVA2KM7:TR?= NWCxVGFJOjV6N{izN|E>
Sup-T1 NIL4WmpEgXSxdH;4bYMhSXO|YYm= Mn3kO|IhcA>? NWLRbGFXTE2VTx?= NUTJe3BtUUN3ME2yMlE1OiEQvF2= MmTQNlU5Pzh|M{G=
Tib 152 MmPPR5l1d3SxeHnjJGF{e2G7 MWW3NkBp M4m4NmROW09? NGG5cYlKSzVyPUCuPEDPxE1? MVyyOVg4QDN|MR?=
MCF7 MlLZSpVv[3Srb36gRZN{[Xl? MoDGOUDPxE1? NF3GPGkzPCCq M1LHfmROW09? MmfJTY5lfWOnczDHNk9OKGG{cnXzeC=> MomyNlU5OzR2MEG=
MDA-MB-231 M4XqTmZ2dmO2aX;uJGF{e2G7 NY\jXG14PSEQvF2= NHHleWozPCCq NV36[4FzTE2VTx?= NFvnboRKdmS3Y3XzJGc{N01iYYLy[ZN1 MUGyOVg{PDRyMR?=
MCF7 MXLGeY5kfGmxbjDBd5NigQ>? M1jM[VUh|ryP MkXYNlQhcA>? M{H0UGROW09? NYHvenFKTGWlcnXhd4V{KHSqZTDlfJBz\XO|aX;uJIxmfmWuIH;mJGNFUzFxQ1TDNi=> MV:yOVg{PDRyMR?=
MCF7 M1LGbmZ2dmO2aX;uJGF{e2G7 NHvzTow2KM7:TR?= NHnBdXkzPCCq NGHXd3hFVVOR NF[1S5dF\WO{ZXHz[ZMhfGinIHX4dJJme3Orb36gcIV3\Wxib3[gR2RMOg>? NVjUOpZiOjV6M{S0NFE>
MCF7 NIiybJRHfW6ldHnvckBCe3OjeR?= Mo\OOUDPxE1? MWqyOEBp Ml:zSG1UVw>? NF:1[WdF\WO{ZXHz[ZMhfGinIHX4dJJme3Orb36gcIV3\Wxib3[gZ5lkdGmwIFKx NY\EO2U6OjV6M{S0NFE>
MCF7 MorySpVv[3Srb36gRZN{[Xl? NYS1fZloPSEQvF2= M2TDU|I1KGh? NV;Md5R3TE2VTx?= NWHSV2FIUW6lcnXhd4V{KHSqZTDlfJBz\XO|aX;uJIxmfmWuIH;mJJAzOSCZYX[xM2NqeDF? M13FblI2QDN2NECx
MCF7 NUjaSoFiTnWwY4Tpc44hSXO|YYm= M{m1V|Uh|ryP NVTyNHVjOjRiaB?= M1TCSWROW09? M1TqNGlv[3KnYYPld{B1cGViZYjwdoV{e2mxbjDs[ZZmdCCxZjDwNlchU2myMR?= MkjLNlU5OzR2MEG=
MDA-MB-231 MX;GeY5kfGmxbjDBd5NigQ>? NVTm[Gc2PSEQvF2= NUW3WZgyOjRiaB?= NYTze|FLTE2VTx?= M{fEZWRm[3KnYYPld{B1cGViZYjwdoV{e2mxbjDs[ZZmdCCxZjDDSGsyN0OGQ{K= MkPLNlU5OzR2MEG=
MDA-MB-231 MkWySpVv[3Srb36gRZN{[Xl? MkTBNUDPxE1? NUDqbXJuOjRiaB?= NYLtenpwTE2VTx?= NYDxVpdFUW6lcnXhd4V{KHSqZTDlfJBz\XO|aX;uJIxmfmWuIH;mJGNFUzJ? NX3XOHVCOjV6M{S0NFE>
MDA-MB-231 MkTvSpVv[3Srb36gRZN{[Xl? MmKyOUDPxE1? MWmyOEBp M2[yc2ROW09? M3:zNGRm[3KnYYPld{B1cGViZYjwdoV{e2mxbjDs[ZZmdCCxZjDjfYNtcW5iQkG= NHLuW5EzPTh|NESwNS=>
MDA-MB-231 Mn:4SpVv[3Srb36gRZN{[Xl? NHnTWoY2KM7:TR?= NH3a[|UzPCCq MlO1SG1UVw>? M4\ieGlv[3KnYYPld{B1cGViZYjwdoV{e2mxbjDs[ZZmdCCxZjDwNlEhX2GoMT;DbZAy MmD6NlU5OzR2MEG=
MDA-MB-231 NWjWVHJOTnWwY4Tpc44hSXO|YYm= MYe1JO69VQ>? NH3ONJQzPCCq MVvEUXNQ NY\pOZh2UW6lcnXhd4V{KHSqZTDlfJBz\XO|aX;uJIxmfmWuIH;mJJAzPyCNaYCx NWG1boN1OjV6M{S0NFE>
MDA-MB-231 MV7GeY5kfGmxbjDBd5NigQ>? NX7qNHhyPSEQvF2= NUT3SIt5OjRiaB?= NHf2N3hFVVOR M3LLOWlv[3KnYYPld{B1cGViZYjwdoV{e2mxbjDs[ZZmdCCxZjDwOVM> NUXsVIo4OjV6M{S0NFE>
MCF7 MmPYRZBweHSxc3nzJGF{e2G7 NYPHSGJpPSEQvF2= MXGyOEBp MknzSG1UVw>? M{HjWGlv\HWlZYOgZZBweHSxdHnjJIRm[XSq NHOwSJAzPTh|NESwNS=>
MDA-MB-231 NXn2VYtpSXCxcITvd4l{KEG|c3H5 M3v6fVUh|ryP M4joTFI1KGh? NXHpT5lNTE2VTx?= MXfJcoR2[2W|IHHwc5B1d3SrYzDk[YF1cA>? NFXYVXIzPTh|NESwNS=>
MCF7 MoizSpVv[3Srb36gRZN{[Xl? MV2xJO69VQ>? NF[1cVg4OiCq NX7VTpVkTE2VTx?= M{H1Umlv\HWlZYOgZZV1d3CqYXfpZ{Bl\WG2aB?= MWOyOVg{PDRyMR?=
MDA-MB-231 M3vWV2Z2dmO2aX;uJGF{e2G7 MoXlNUDPxE1? NFG3b4s4OiCq NEDQPG5FVVOR NH\5dXhKdmS3Y3XzJIF2fG:yaHHnbYMh\GWjdHi= NES4SWQzPTh|NESwNS=>
U-2 OS M3\XW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4fveVUxKM7:TR?= MWCyOEBp NH;aenJFVVOR NGGwe|VKSzVyPUG2MlYh|ryP NFvRZ4YzPTd7MkixNS=>
MG-63 MoP4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHHNN5Q2OCEQvF2= M2DHWlI1KGh? MmfpSG1UVw>? MlTWTWM2OD17LkWg{txO M33ufFI2Pzl{OEGx
U-2 OS MXvBdI9xfG:|aYOgRZN{[Xl? NGC2e2s2KM7:TR?= MoHTNlQhcA>? MXnEUXNQ MkPPTY5lfWOnczDhdI9xfG:2aXOgZ4VtdCCmZXH0bC=> M4PmR|I2Pzl{OEGx
MG-63 M3n6fGFxd3C2b4Ppd{BCe3OjeR?= MXu1JO69VQ>? MmrlNlQhcA>? MoDtSG1UVw>? NITiUm5KdmS3Y3XzJIFxd3C2b4TpZ{Bk\WyuIHTlZZRp MY[yOVc6OjhzMR?=
U-2 OS NETP[4NHfW6ldHnvckBCe3OjeR?= MUi1JO69VQ>? MViyOEBp Mnm0SG1UVw>? M{K0WHBzd22xdHXzJIF2fG:yaHHnbYMh[2WubDDk[YF1cA>? M1TUe|I2Pzl{OEGx
MG-63 NIP1SpVHfW6ldHnvckBCe3OjeR?= NWXwZYtrPSEQvF2= NYr0VFhsOjRiaB?= M4\6OmROW09? MkSwVJJwdW:2ZYOgZZV1d3CqYXfpZ{Bk\WyuIHTlZZRp NEHLNpQzPTd7MkixNS=>
PANC-1 NIPxeoRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MonHOVAh|ryP M3HBUlI1KGh? NFOzPVVFVVOR NV\HZXlQUUN3ME23MlEh|ryP NWHtW2s6OjV4M{KyNlU>
BxPC-3 NGHsdoxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHu3c4k2OCEQvF2= MlnPNlQhcA>? NHjRZYVFVVOR MWnJR|UxRTZwODFOwG0> NGPxZ|czPTZ|MkKyOS=>
PANC-1 MUfGeY5kfGmxbjDBd5NigQ>? NY\3TIc4PSEQvF2= M3\lNVI1KGh? MnP4SG1UVw>? M{i4Nmlv\HWlZYOgZ4VtdCCleXPs[UBienKnc4SgbY4hTzJxTTDwbIF{\Q>? NHf3[4gzPTZ|MkKyOS=>
BxPC-3 M2nvb2Z2dmO2aX;uJGF{e2G7 MWG1JO69VQ>? MnW2NlQhcA>? NVfFXoU5TE2VTx?= NVnNR4FjUW6mdXPld{Bk\WyuIHP5Z4xmKGG{cnXzeEBqdiCJMj;NJJBp[XOn MnznNlU3OzJ{MkW=
PANC-1 MVzGeY5kfGmxbjDBd5NigQ>? MXm1JO69VQ>? NFi0UGczPCCq MX\EUXNQ NU\3SmZRUW6mdXPld{BifXSxcHjh[4lkKGOnbHyg[IVifGh? MVKyOVY{OjJ{NR?=
BxPC-3 NV7nSZJoTnWwY4Tpc44hSXO|YYm= MmPnOUDPxE1? NWiz[Xc1OjRiaB?= NE\yeIlFVVOR M4XvbGlv\HWlZYOgZZV1d3CqYXfpZ{Bk\WyuIHTlZZRp NHjB[4wzPTZ|MkKyOS=>
SKOV3 MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVTXZpNTOTByIN88US=> M3G5ZlI1KGh? MY\EUXNQ MYHJR|UxRTJyLkS4JO69VQ>? NUjoW5ZNOjV4MkS3OVA>
OVCAR4 MoSzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlqxNVAxKM7:TR?= NGf6SW8zPCCq MmDySG1UVw>? NFe1d|lKSzVyPUKyMlE{KM7:TR?= NHfRZ3czPTZ{NEe1NC=>
SKOV3 NHTjRXRHfW6ldHnvckBCe3OjeR?= NXi4d4xCPSEQvF2= M2\iRlczKGh? MVzEUXNQ NVPZW2JDUW6mdXPld{BIOi:PIHHydoV{fA>? NHzZWm0zPTZ{NEe1NC=>
OVCAR4 M4nC[2Z2dmO2aX;uJGF{e2G7 MWm1JO69VQ>? NITCPYs4OiCq MnzTSG1UVw>? MYXJcoR2[2W|IFeyM20h[XK{ZYP0 M3niUVI2PjJ2N{Ww
SKOV3 NEC2ZXFCeG:ydH;zbZMhSXO|YYm= MWO1JO69VQ>? NIXremwzPCCq M1i4WGROW09? MoK1TY5lfWOnczDhdI9xfG:|aYO= MYWyOVYzPDd3MB?=
OVCAR4 NFrwXZJCeG:ydH;zbZMhSXO|YYm= M4rtR|Uh|ryP NH7uS|QzPCCq MoHWSG1UVw>? MYnJcoR2[2W|IHHwc5B1d3Orcx?= NHHNSpAzPTZ{NEe1NC=>
AGS M3XkcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVKyOUDPxE1? M2Lpb|I1KGh? M1jLU2ROW09? NFLXW3lKSzVyPUG5MlA6KM7:TR?= NFPhN44zPTZyOUmyNy=>
NCI-N78 Moe1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXLNbY1DOjVizszN MXGyOEBp M3:xV2ROW09? NVPFN4dNUUN3ME2yOk4{OyEQvF2= MVWyOVYxQTl{Mx?=
AGS NUTod2RGSXCxcITvd4l{KEG|c3H5 MUm1JO69VQ>? NIH6PHAzPCCq Mm\jSG1UVw>? NUC4Vo1uUW6mdXPld{BieG:ydH;zbZM> NIjx[IMzPTZyOUmyNy=>
NCI-N78 NF3KOohCeG:ydH;zbZMhSXO|YYm= NIPxU|Y2KM7:TR?= NEf4TGIzPCCq NXPseXlkTE2VTx?= M{PMbmlv\HWlZYOgZZBweHSxc3nz MU[yOVYxQTl{Mx?=
AGS MmXPSpVv[3Srb36gRZN{[Xl? NGPpdGM2KM7:TR?= NXXzSlVROjRiaB?= NVO3UYlETE2VTx?= NFPhc4hKdmS3Y3XzJJRp\SCjdYTvdIhi\3l? NFLnflYzPTZyOUmyNy=>
NCI-N78 MUXGeY5kfGmxbjDBd5NigQ>? M3X0U|Uh|ryP MWOyOEBp NHXY[JZFVVOR MYnJcoR2[2W|IITo[UBifXSxcHjh[5k> MX6yOVYxQTl{Mx?=
HSC-3 MnP1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEnocFUyKM7:TR?= M3jOdlQ5KGh? MorkTWM2OD1yLkW0JO69VQ>? M4nnPVI2OzZ4MUSz
GB30 MmHjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{DVelEh|ryP NUfjXYt3PyCm M2TEVGROW09? NVn3U3FbUUN3ME2wMlAyOSEQvF2= NHrYfYgzPTFyNkSyPC=>
GB9 M4[0N2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3zLV|Eh|ryP M2Tnclch\A>? NHS1[lBFVVOR M2SwcmlEPTB;MD6wNlQh|ryP MUKyOVExPjR{OB?=
GB169 MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEe4N2QyKM7:TR?= NXXadplsPyCm NUTocHkzTE2VTx?= MofrTWM2OD1yLkCzNkDPxE1? MnfFNlUyODZ2Mki=
T24 MlezSpVv[3Srb36gRZN{[Xl? MXuxJO69VQ>? MUi0PEBp MkPrSG1UVw>? Ml;rTY5lfWOnczDj[YxtKGO7Y3zlJIFzemW|dB?= M{G0XVI{PDB|NkOz
RT4 MlWwSpVv[3Srb36gRZN{[Xl? MVuxJO69VQ>? MX20PEBp NXLPbWJ4TE2VTx?= NGL2bI1KdmS3Y3XzJINmdGxiY4njcIUh[XK{ZYP0 NXn0VotvOjN2MEO2N|M>
UM-UC-3 NV60WHpxTnWwY4Tpc44hSXO|YYm= MUmxJO69VQ>? MXq0PEBp M{PMV2ROW09? NY\WRllkUW6mdXPld{Bk\WyuIHP5Z4xmKGG{cnXzeC=> MX6yN|QxOzZ|Mx?=
T24 M37nXGFxd3C2b4Ppd{BCe3OjeR?= MkLyN{4yPiEQvF2= MXS5OkBp M{jUbmROW09? MVzJR|UxRTBwMEOwOkDPxE1? M{CwSlI{PDB|NkOz
RT4 NEj3[4RCeG:ydH;zbZMhSXO|YYm= MmXyN{4yPiEQvF2= NYO4[IVmQTZiaB?= NEPQNlZFVVOR MXnJR|UxRTBwMUG5PEDPxE1? NUj4cYh3OjN2MEO2N|M>
UM-UC-3 NIDyN5dCeG:ydH;zbZMhSXO|YYm= Mln6N{4yPiEQvF2= MWe5OkBp MVLEUXNQ M3\DSmlEPTB;MD6wOFQ6KM7:TR?= NGrobGYzOzRyM{[zNy=>
OVCAR-5 NEO2UnVHfW6ldHnvckBCe3OjeR?= NV:3PGc{PTBibl2= NYe1NlM4UW6qaXLpeJMh[2WubDDtbYdz[XSrb36= MWqyN|M{PDN{Nx?=
SKOV3ip2 MVXGeY5kfGmxbjDBd5NigQ>? MWq1NEBvVQ>? NE\JN4dKdmirYnn0d{Bk\WyuIH3p[5JifGmxbh?= MUeyN|M{PDN{Nx?=
S462 MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUTmZlZuOTByIN88US=> NYnR[os1PzJiaB?= Mnz6SG1UVw>? Mlv5RZR1\W63YYTld{Bk\WyuIHfyc5d1cA>? NHq1fGEzOzN{OEGxOC=>
2884 NXjqeos3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXSxNFAh|ryP MVe3NkBp M1T4[GROW09? Mk\HRZR1\W63YYTld{Bk\WyuIHfyc5d1cA>? MXGyN|MzQDFzNB?=
2885 M3\Tfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWGxNFAh|ryP MVG3NkBp NVLqfFljTE2VTx?= M{XjVGF1fGWwdXH0[ZMh[2WubDDndo94fGh? NEHMTHYzOzN{OEGxOC=>
CRL-2396 NFPoc2RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3XE[VExOCEQvF2= NYO4VZd1f2G2ZYK= NXfIN5dZUUN3ME2wMlA6OiEQvF2= MoPlNlMyPTN3MkS=
TIB-48 MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlvqNVAxKM7:TR?= MUD3ZZRmeg>? NUDkOJB7UUN3ME2wMlA5QCEQvF2= NHXRUXYzOzF3M{WyOC=>
CRL-2396 NFTFTXpEgXSxdH;4bYMhSXO|YYm= MoH0NUDPxE1? MWC0PEBp Mlfue4F1\XJ? NInTNodKdmS3Y3XzJIFxd3C2b4Ppdy=> M1LKVlI{OTV|NUK0
TIB-48 M1\PPGN6fG:2b4jpZ{BCe3OjeR?= M2q4fFEh|ryP M{\Bd|Q5KGh? MofWe4F1\XJ? NW\PXY1wUW6mdXPld{BieG:ydH;zbZM> MYqyN|E2OzV{NB?=
AGS M4XBXWN6fG:2b4jpZ{BCe3OjeR?= NYLacWdIOC53IN88US=> MWOyOEBp NGS1XWhFVVOR MlvLSIVkemWjc3XzJINmdGxic4Xyeol3[Wx? NEHW[2MzOjl5Mk[xNS=>
FLO-1 M{TwOGN6fG:2b4jpZ{BCe3OjeR?= NXj5fYtwOC53IN88US=> NEjKOFEzPCCq Mn3FSG1UVw>? M1fZNmRm[3KnYYPld{Bk\WyuIIP1dpZqfmGu NVjxeYozOjJ7N{K2NVE>
OE33 M4XaRWN6fG:2b4jpZ{BCe3OjeR?= NWDZOZVKOC53IN88US=> NVzvcHY6OjRiaB?= MWHEUXNQ NGK2cYRF\WO{ZXHz[ZMh[2WubDDzeZJ3cX[jbB?= NHy4fVgzOjl5Mk[xNS=>
SKLMS NGHUcolEgXSxdH;4bYMhSXO|YYm= NV\KfVZJPzVibl2= Mnu2PVYhcA>? NFTZW3NKdmS3Y3XzJIFxd3C2b4Ppdy=> MmHTNlI5OjF7OUe=
Leio285 MUXDfZRwfG:6aXOgRZN{[Xl? NVnuPVlpPzVibl2= MWG5OkBp M2nZRWlv\HWlZYOgZZBweHSxc3nz NUfRS5RFOjJ6MkG5PVc>
Mes-Sa Mnv0R5l1d3SxeHnjJGF{e2G7 MYi3OUBvVQ>? MYm5OkBp Mmr4TY5lfWOnczDhdI9xfG:|aYO= NYrsXFRjOjJ6MkG5PVc>
DAOY MVTDfZRwfG:6aXOgRZN{[Xl? MXqxNEDPxE1? NIfnWHk4OiCq NHzDUoxFVVOR NYfq[FJjUUN3ME2wMlA1KM7:TR?= NFSzeGMzOjZ4OUOzOS=>
IMR32 M3juNGN6fG:2b4jpZ{BCe3OjeR?= NFPKfFMyOCEQvF2= MUW3NkBp NYO3fXc4TE2VTx?= NWG0fWdpUUN3ME2wMlA{KM7:TR?= MUKyNlY3QTN|NR?=
Molt-4 MlfJR5l1d3SxeHnjJGF{e2G7 M4HTflExKM7:TR?= MoXEO|IhcA>? M2TCS2ROW09? MkK2TWM2OD1yLkCyJO69VQ>? MX:yNlY3QTN|NR?=
MOLM-13 NFnSb5ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1qyWVMh|ryP MWi3NkBp M1fBTmRqdWmwaYPo[ZMh[2WubDD2bYFjcWyrdIm= NEXXc2YzOjR6OEK0PS=>
HL-60 NIfvRlFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoC4N{DPxE1? NV\OSY9sPzJiaB?= M4ezPWRqdWmwaYPo[ZMh[2WubDD2bYFjcWyrdIm= NVrae45rOjJ2OEiyOFk>
MV4-11 M2jVWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmS5N{DPxE1? Mn\zO|IhcA>? NEf6VJdFcW2rbnnzbIV{KGOnbHygeoli[mmuaYT5 M4fVXFIzPDh6MkS5
SKM-1 M4LT[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXWzJO69VQ>? MVW3NkBp MV;EbY1qdmm|aHXzJINmdGxidnnhZoltcXS7 Mn\tNlI1QDh{NEm=
SH2 NWHHdJdJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1LsVFMh|ryP NWXzZXhMPzJiaB?= MorCSIlucW6rc3jld{Bk\WyuII\pZYJqdGm2eR?= MmPnNlI1QDh{NEm=
NOMO-1 MnrRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXmzJO69VQ>? NUXsW2RmPzJiaB?= NVftRY4xTGmvaX7pd4hmeyClZXzsJJZq[WKrbHn0fS=> NFT4fmkzOjR6OEK0PS=>
OCL-AML2 NVjTUpM5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlzLN{DPxE1? NIGze3c4OiCq MXjEbY1qdmm|aHXzJINmdGxidnnhZoltcXS7 NUTVcnQ6OjJ2OEiyOFk>
PL-21 M4rtcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NITTV4Y{KM7:TR?= Mn3sO|IhcA>? NF\xbHFFcW2rbnnzbIV{KGOnbHygeoli[mmuaYT5 NXLufGxxOjJ2OEiyOFk>
KG-1 NFTGXGZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4TEcVMh|ryP M2juNFczKGh? M1q1NmRqdWmwaYPo[ZMh[2WubDD2bYFjcWyrdIm= MlvhNlI1QDh{NEm=
A172 M1LVeGN6fG:2b4jpZ{BCe3OjeR?= M3\TPFExOCEQvF2= NYrTZ5RpOjRiaB?= M3vFc2ROW09? M4fremlEPTB;MD6xNlAh|ryP MVGyNlI4PDN7OR?=
U87 MXfDfZRwfG:6aXOgRZN{[Xl? M1HmfVExOCEQvF2= M2PwZlI1KGh? NV:5VIdnTE2VTx?= Ml7ZTWM2OD1yLkGwOUDPxE1? NEjNbHYzOjJ5NEO5PS=>
U251 MlrVR5l1d3SxeHnjJGF{e2G7 MWqxNFAh|ryP MlLyNlQhcA>? NXW1fooxTE2VTx?= NXG2T2dqUUN3ME2wMlExOCEQvF2= MX[yNlI4PDN7OR?=
T98 M4rVSmN6fG:2b4jpZ{BCe3OjeR?= NWe3dWF5OTByIN88US=> NYnSWXZPOjRiaB?= MmPOSG1UVw>? MVnJR|UxRTBwMUK1JO69VQ>? MWKyNlI4PDN7OR?=
LN18 MV;DfZRwfG:6aXOgRZN{[Xl? M{fXRlExOCEQvF2= NVPD[pc{OjRiaB?= Mni3SG1UVw>? MlizTWM2OD1yLkKxNEDPxE1? NWHUToxrOjJ{N{SzPVk>
LN443 M4LROmN6fG:2b4jpZ{BCe3OjeR?= NV7EfIpLOTByIN88US=> MnziNlQhcA>? M2jQVWROW09? NY\CSohwUUN3ME2wMlIzOCEQvF2= NVrBd|d5OjJ{N{SzPVk>
HF66 M1z1d2N6fG:2b4jpZ{BCe3OjeR?= NWqz[GFoOTByIN88US=> NYniZW1iOjRiaB?= M{C2WmROW09? NIfkXXBKSzVyPUCuNlI2KM7:TR?= MorJNlIzPzR|OUm=
HF2303 M4rmXWN6fG:2b4jpZ{BCe3OjeR?= MWixNFAh|ryP MWSyOEBp NHnJemVFVVOR NVv4XplFUUN3ME2wMlA3OCEQvF2= NVTJ[2h7OjJ{N{SzPVk>
HF2359 MmmxR5l1d3SxeHnjJGF{e2G7 M1frOlExOCEQvF2= M3HoRlI1KGh? MX\EUXNQ NVPHbo04UUN3ME2wMlA3OCEQvF2= MmjrNlIzPzR|OUm=
HF2414 M1yzNWN6fG:2b4jpZ{BCe3OjeR?= NWPBZlg6OTByIN88US=> Mn\ZNlQhcA>? NYrieYhHTE2VTx?= MluwTWM2OD1yLkC4NEDPxE1? MnTPNlIzPzR|OUm=
A-673 MkD0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mkm4NVAh|ryP MXW5OkBp MnfMSG1UVw>? MVHJR|UxRTBwMEOyJO69VQ>? NFKwNGgzOTR2OEW5NS=>
TC-32 NE\RNHpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3rGV|ExKM7:TR?= M1fRcFk3KGh? NWP4UI1oTE2VTx?= M1T0c2lEPTB;MD6wN|kh|ryP MV2yNVQ1QDV7MR?=
TC-71 M4nN[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXyxNEDPxE1? MXS5OkBp MWfEUXNQ MlHNTWM2OD1yLkGwNkDPxE1? NGGzVI4zOTR2OEW5NS=>
SK-N-MC MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{nicVExKM7:TR?= MkTwPVYhcA>? MofmSG1UVw>? MV7JR|UxRTBwMEeyJO69VQ>? M1;HZ|IyPDR6NUmx
CHLA-9 Mmj2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWqyU28zOTBizszN M1nlPFk3KGh? Mo\uSG1UVw>? M1P1bGlEPTB;MD6wNVgh|ryP MVWyNVQ1QDV7MR?=
CHLA-10 MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWD4NHpQOTBizszN MlLCPVYhcA>? NHqzco9FVVOR NGnneYVKSzVyPUCuNFYxKM7:TR?= MkP3NlE1PDh3OUG=
CHLA-25 M2H5UGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGqw[FMyOCEQvF2= M1m1eFk3KGh? M2P6e2ROW09? M33YVWlEPTB;MD6xOlgh|ryP MlHrNlE1PDh3OUG=
CHLA-32 NEfGUodIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1K3Z|ExKM7:TR?= M3;WeVk3KGh? M3XM[mROW09? NEjTRmJKSzVyPUCuNVM3KM7:TR?= MlznNlE1PDh3OUG=
CHLA-56 MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVvIR2ZLOTBizszN NU\CeZlUQTZiaB?= NUPk[WlZTE2VTx?= M{HsUWlEPTB;MUCg{txO M4LofFIyPDR6NUmx
CHLA-258 M{n6[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2jX[VExKM7:TR?= MVe5OkBp M4TmfmROW09? Mn\pTWM2OD1yLkGzNkDPxE1? NYPlU4Z2OjF2NEi1PVE>
COG-E-352 MmWzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVrRXWFZOTBizszN NHX1Xlk6PiCq M1P1fWROW09? NXu1XotEUUN3ME2wMlA1OyEQvF2= NInZflYzOTR2OEW5NS=>
CHLA-90 M3vZ[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{HOPVExKM7:TR?= MUC5OkBp NIPoNYhFVVOR M4nn[WlEPTB;MD6wOlEh|ryP NFezeFIzOTR2OEW5NS=>
CHLA-119 NYPlbWVJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGnzNVIyOCEQvF2= NWnIWZlCQTZiaB?= MmXnSG1UVw>? NVXFWmNoUUN3ME2wMlAzOiEQvF2= M4e5PFIyPDR6NUmx
CHLA-122 Mm\ES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYDTVVB{OTBizszN M4HNVVk3KGh? NHHKNmhFVVOR NFLzZmdKSzVyPUCuNFE6KM7:TR?= M2KyV|IyPDR6NUmx
CHLA-136 M{XQWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmfFNVAh|ryP MoLIPVYhcA>? MUXEUXNQ NUmzVZRVUUN3ME2wMlA{QSEQvF2= NIDTO|IzOTR2OEW5NS=>
CHLA-140 MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2LCZlExKM7:TR?= MUS5OkBp MkTVSG1UVw>? M1;nT2lEPTB;MD6wNlYh|ryP M3zuNVIyPDR6NUmx
LA-N-6 M2i0UWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHfYR3MyOCEQvF2= NH;yWZA6PiCq NYjhUIdbTE2VTx?= NYfuNFJOUUN3ME2wMlA2PCEQvF2= NWPYRW8yOjF2NEi1PVE>
NB-1643 Mnm3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYixNEDPxE1? M{jiVVk3KGh? M4HJ[mROW09? MoPCTWM2OD1yLkCzO{DPxE1? NGK1eVczOTR2OEW5NS=>
NB-EBc1 MoTmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXWxNEDPxE1? NGPrb4U6PiCq M1ztNmROW09? MoTSTWM2OD1yLkC1NEDPxE1? NUnvdlhSOjF2NEi1PVE>
SK-N-BE-1 NInHR|RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoHHNVAh|ryP MkXvPVYhcA>? MX7EUXNQ Mkj1TWM2OD1yLkCyPEDPxE1? MV2yNVQ1QDV7MR?=
SK-N-BE-2 MlrvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEPib|AyOCEQvF2= M2LoUFk3KGh? M4\Jb2ROW09? MlPhTWM2OD1yLkCzOkDPxE1? NFnOeGozOTR2OEW5NS=>
SMS-KAN M2HoOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVyxNEDPxE1? MUi5OkBp M1HCeGROW09? NE\vfJJKSzVyPUCuNFM1KM7:TR?= NGfmZmIzOTR2OEW5NS=>
SMS-KANR NYK0OIZKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEf6U|kyOCEQvF2= M{XBTFk3KGh? NFXa[Y1FVVOR Mkf6TWM2OD1yLkCyOkDPxE1? MmLhNlE1PDh3OUG=
SMS-KCN MoHGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1jJTlExKM7:TR?= MoXXPVYhcA>? NWW2[GliTE2VTx?= NYj1Snd1UUN3ME2wMlAyQSEQvF2= M4XIdFIyPDR6NUmx
SMS-KCNR NGnxfGdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NV3oW5o3OTBizszN MmTmPVYhcA>? M4rlPGROW09? MkjrTWM2OD1yLkCxNEDPxE1? MV2yNVQ1QDV7MR?=
SMS-LHN M3naO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlnONVAh|ryP M37Gd|k3KGh? NITvfXBFVVOR M3f1fmlEPTB;MD6wN|Ih|ryP NX;oW3pvOjF2NEi1PVE>
SMS-MSN MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWixNEDPxE1? NGPoN5g6PiCq M4PDc2ROW09? NITIW|lKSzVyPUCuNFIzKM7:TR?= M4DiW|IyPDR6NUmx
SMS-SAN MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYSxNEDPxE1? NYfBVGs3QTZiaB?= MkS1SG1UVw>? NE[1R5ZKSzVyPUCuNFIxKM7:TR?= MWGyNVQ1QDV7MR?=
Granta-4 MnS3R5l1d3SxeHnjJGF{e2G7 NIWzdocyOCEQvF2= NWLTWog{PyCm MVfJR|UxRTBwMESwJO69VQ>? M2\tOFIyOjlzOE[3
DB Mn;CR5l1d3SxeHnjJGF{e2G7 MXyxNEDPxE1? MkLnO{Bl MlntTWM2OD1yLkC0NkDPxE1? NFzKdo8zOTJ7MUi2Oy=>
RL MoC4R5l1d3SxeHnjJGF{e2G7 MnPhNVAh|ryP MYe3JIQ> M2r4dmlEPTB;MD6wNVUh|ryP MnizNlEzQTF6Nke=
K562 MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{jLRVExKM7:TR?= MmjiPVYhcA>? NF;Kd3RKSzVyPUCuNFg4KM7:TR?= NWHlXI9IOjFyOUG2N|M>
LAMA-84 Ml[4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV\lPXRCOTBizszN MVi5OkBp M{jmZ2lEPTB;MD6wOVch|ryP NVjsVI83OjFyOUG2N|M>
MM15 Ml;oS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{fpbVQh|ryP NV;ofY4{PzJiaB?= NGXaV5pFVVOR M4WzSmlEPTB;MD6xN{DPxE1? MWWyNFM5Ojh2NB?=
OPM1 NF7JNHdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEnpbGo1KM7:TR?= NIrOVo04OiCq NYOxfo0xTE2VTx?= M4q3emlEPTB;MD6wN{DPxE1? M{PuflIxOzh{OES0
RPM1 NHzBdpVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIiwfYg1KM7:TR?= NX\lXVlTPzJiaB?= NHzORVJFVVOR M3LHdGlEPTB;MUCuN|Ih|ryP NV;rUWl6OjB|OEK4OFQ>
INA6 NXrqXFhkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXW0JO69VQ>? NWH6VohjPzJiaB?= M4fyOWROW09? MYTJR|UxRTBwMECyJO69VQ>? NVjXdnUzOjB|OEK4OFQ>
OPM2 NYjBVo55T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmPGOEDPxE1? Mnm4O|IhcA>? MUXEUXNQ NInrcXBKSzVyPUSuN|ch|ryP M4L0[|IxOzh{OES0
MM1R NHzsXFBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkLyOEDPxE1? MX:3NkBp Moe2SG1UVw>? NWnnNIg1UUN3ME2xMlY5KM7:TR?= M1zZZlIxOzh{OES0
DOX40 NHLENXVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEDId3I1KM7:TR?= MmX4O|IhcA>? MXfEUXNQ M13tdGlEPTB;NT60PEDPxE1? MXOyNFM5Ojh2NB?=
LR5 NYLRSGo4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{XjbVQh|ryP MkfCO|IhcA>? M2n3TGROW09? M1fOOmlEPTB;Mj61N{DPxE1? MY[yNFM5Ojh2NB?=
U266 M1H4cmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFuxZVI1KM7:TR?= NFziTZM4OiCq NWLxNWUzTE2VTx?= NEe1c2NKSzVyPUGuOFMh|ryP NXniPVRFOjB|OEK4OFQ>
RD NX3WV|htT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWTsOJcxOTBizszN MkHSPVYhcA>? MnnkTWM2OD1yLkKyPEDPxE1? Mm\ZNlAyODh|M{i=
Rh41 Ml2zS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEHsZmsyOCEQvF2= NUDlTXU1QTZiaB?= NF\BclJKSzVyPUCuNFkxKM7:TR?= NH3yWWEzODFyOEOzPC=>
Rh30 M1vNemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NE\NfoYyOCEQvF2= M{jFfFk3KGh? NV\4VmFkUUN3ME2wMlI{OCEQvF2= NU[wToVKOjBzMEizN|g>
BT-12 NIG2ZXJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIHScoMyOCEQvF2= MUe5OkBp MXTJR|UxRTBwME[wJO69VQ>? NWTOT4FkOjBzMEizN|g>
CHLA-266 MonRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2KzWlExKM7:TR?= NEDqWoY6PiCq NH;XNVZKSzVyPUCuNFczKM7:TR?= NEHUTVUzODFyOEOzPC=>
TC-71 NVfiO49KT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NX;X[|F2OTBizszN M1nHNlk3KGh? NH2zUnJKSzVyPUCuNVAzKM7:TR?= NIDtco0zODFyOEOzPC=>
SJ-GBM2 MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFPkNWgyOCEQvF2= MUi5OkBp MVjJR|UxRTBwMEWwJO69VQ>? MYCyNFExQDN|OB?=
NALM-6 NWfDfXhET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUixNEDPxE1? MlX2PVYhcA>? MXTJR|UxRTBwME[yJO69VQ>? NFXjdIkzODFyOEOzPC=>
COG-LL-317 MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NH73XnQyOCEQvF2= NHKyRnk6PiCq NX63c4F1UUN3ME2wMlA1PyEQvF2= MlrsNlAyODh|M{i=
RS4-11 MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWmxNEDPxE1? MoPVPVYhcA>? MmjLTWM2OD1yLkCxPEDPxE1? MWOyNFExQDN|OB?=
MOLT-4 NYjGNIRST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWTNO2dnOTBizszN M{HTXVk3KGh? NHLGU2RKSzVyPUCuNFI3KM7:TR?= MmrGNlAyODh|M{i=
CCRF-CEM NYH3fI84T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEjhOGIyOCEQvF2= NEjsZZE6PiCq MVvJR|UxRTBwMEm0JO69VQ>? NF7KWlczODFyOEOzPC=>
Kasumi-1 MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmHoNVAh|ryP MWK5OkBp NEXhdIVKSzVyPUCuNVA{KM7:TR?= M2rqOFIxOTB6M{O4
Karpas-299 MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHT4VXMyOCEQvF2= M1f4Ulk3KGh? M3;oUmlEPTB;MD6wN|gh|ryP NYrZe|FMOjBzMEizN|g>
Ramos-RA1 M3XNSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVr6dnZGOTBizszN NHqyc|M6PiCq MnS5TWM2OD1yLkGyO{DPxE1? MnfBNlAyODh|M{i=

... Click to View More Cell Line Experimental Data

In vivo MLN8237 significantly reduces the tumor burden with tumor growth inhibition (TGI) of 42% and 80% at 15 mg/kg and 30 mg/kg, respectively, and prolongs the survival of mice compared with the control. [2]

Protocol

Kinase Assay:[1]
+ Expand

Aurora A radioactive Flashplate enzyme assay:

Aurora A radioactive Flashplate enzyme assay is conducted to determine the nature and degree of MLN8237-mediated inhibition in vitro. Recombinant Aurora A is expressed in Sf9 cells and purified with GST affinity chromatography. The peptide substrate for Aurora A is conjugated with biotin (Biotin-GLRRASLG). Aurora A kinase (5 nM) is assayed in 50 mM Hepes (pH 7.5), 10 mM MgCl2, 5 mM DTT, 0.05% Tween 20, 2 μM peptide substrate, 3.3 μCi/mL [γ-33P]ATP at 2 μM, and increasing concentrations of MLN8237 by using Image FlashPlates.
Cell Research:[2]
+ Expand
  • Cell lines: MM1.S, MM.1R, LR5, RPMI 8226, DOX40, OPM1, OPM2, INA6, and U266
  • Concentrations: Dissolved in DMSO, final concentrations ~10 μM
  • Incubation Time: 24, 48, and 72 hours
  • Method: Cells are exposed to various concentrations of MLN8237 for 24, 48, and 72 hours. Cells viability is measured using MTT assay, and cell proliferation is measured using 3[H]-thymidine incorporation. For cell cycle analysis, cells are permeabilized by 70% ethanol at -20 °C, and incubated with 50 μg/mL PI and 20 units/mL RNase-A. DNA content is analyzed by flow cytometry using BDFACS-Canto II and FlowJo software. For the detection of apoptosis and senescence, cells are stained with fluorescein isothiocyanate-annexin V and PI. Apoptotic cells are determined by flow cytometric analysis using BDFACS-Canto II and FlowJo software.
    (Only for Reference)
Animal Research:[2]
+ Expand
  • Animal Models: Severe combined immune-deficient (SCID) mice inoculated subcutaneously with MM1.S cells
  • Formulation: Formulated in 10% 2-hydroxypropyl-β-cyclodextrin/1% sodium bicarbonate
  • Dosages: ~30 mg/kg/day
  • Administration: Orally
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 27 mg/mL (52.03 mM)
Water Insoluble
Ethanol Insoluble
In vivo Add solvents individually and in order:
15% Captisol
30 mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 518.92
Formula

C27H20ClFN4O4

CAS No. 1028486-01-2
Storage powder
Synonyms N/A

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT02860000 Not yet recruiting Estrogen Receptor Negative|Estrogen Receptor Positive|HER2/Neu Negative|Postmenopausal|Stage IIIA Breast Cancer|Stage IIIB Breast Cancer|Stage IIIC Breast Cancer|Stage IV Breast Cancer Mayo Clinic|National Cancer Institute (NCI) December 2016 Phase 2
NCT02812056 Not yet recruiting Malignant Neoplasms of Digestive Organs|Malignant Neoplasms of Female Genital Organs|Malignant Neoplasms of Lip Oral Cavity and Pharynx|Malignant Neoplasms of Male Genital Organs M.D. Anderson Cancer Center|Millennium Pharmaceuticals, Inc. September 2016 Phase 1
NCT02700022 Recruiting Diffuse Large B-cell Lymphoma|Follicular Lymphoma|Burkitt Lymphoma UNC Lineberger Comprehensive Cancer Center|Millennium Pharmaceuticals, Inc. July 2016 Phase 1
NCT02719691 Recruiting Metastatic Breast Cancer|Solid Tumors University of Colorado, Denver May 2016 Phase 1
NCT02560025 Recruiting Acute Myeloid Leukemia Massachusetts General Hospital|Takeda December 2015 Phase 2
NCT02551055 Active, not recruiting Neoplasms, Advanced or Metastatic Millennium Pharmaceuticals, Inc.|Takeda October 2015 Phase 1

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Frequently Asked Questions

  • Question 1:

    What is the suggested formulation of this compound for mouse injection(i.p.)?

  • Answer:

    It can be dissolved in 6% DMSO/50% PEG 300/5% Tween 80/ddH2O at 10 mg/ml as a clear solution.

Related Antibodies

Aurora Kinase Signaling Pathway Map

Aurora Kinase Inhibitors with Unique Features

Related Aurora Kinase Products

Tags: buy Alisertib (MLN8237) | Alisertib (MLN8237) supplier | purchase Alisertib (MLN8237) | Alisertib (MLN8237) cost | Alisertib (MLN8237) manufacturer | order Alisertib (MLN8237) | Alisertib (MLN8237) distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID